logo
Twitter
Discord
Email
logo
OrthoPediatrics Corp.

OrthoPediatrics Corp.

NASDAQ•KIDS
CEO: Mr. Mark C. Throdahl
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2017-10-13
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Contact Information
2850 Frontier Drive, Warsaw, IN, 46582, United States
574-268-6379
www.orthopediatrics.com
Market Cap
$441.36M
P/E (TTM)
-9.0
33
Dividend Yield
--
52W High
$27.60
52W Low
$15.28
52W Range
19%
Rank71Top 96.3%
1.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$61.25M+12.23%
4-Quarter Trend

EPS

-$0.50+47.06%
4-Quarter Trend

FCF

-$3.42M-70.67%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Net revenue reached $174.7M for nine months, up 15%, driven by Trauma/Deformity and Scoliosis sales.
Financing Secured Company drew $25.0M from the delayed draw term loan facility on June 27, 2025, enhancing liquidity.
Acquisition Integration Continues Multiple O&P clinics acquired through September 30, 2025, for total consideration of approximately $6.02M.
Cash Position Maintained Cash, equivalents, and restricted cash totaled $18.9M as of September 30, 2025, supporting operations.

Risk Factors

Net Loss Widened Nine-month net loss increased 36% to $(29.5M) due to rising operating expenses and restructuring costs.
Goodwill Impairment Recorded Recorded $1.9M goodwill impairment charge following the decision to exit the Telos regulatory consulting business.
Operating Costs Increased Total operating expenses rose 18.4% to $158.6M for nine months, driven by commissions and personnel costs.
Trade Policy Uncertainty Subject to risks from international trade changes, including tariffs and geopolitical shifts impacting product costs.

Outlook

Strategic Market Expansion Plans include strengthening U.S. and international markets via infrastructure investment and expanding product offerings.
Cash Preservation Strategy Ongoing efforts include settling MedTech cash payments via unregistered common stock issuance instead of cash.
Liquidity Forecast Positive Management believes current cash balance is sufficient to maintain operations for more than the next twelve months.
Focus on Core Market Continue exclusive focus on pediatric orthopedic trauma, deformity correction, and sports medicine product offerings.

Peer Comparison

Revenue (TTM)

Varex Imaging CorporationVREX
$844.60M
+4.1%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%
Bioventus Inc.BVS
$563.83M
+1.6%

Gross Margin (Latest Quarter)

Treace Medical Concepts, Inc.TMCI
79.1%
-1.1pp
NeuroPace, Inc.NPCE
77.4%
+4.2pp
OrthoPediatrics Corp.KIDS
73.9%
+0.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CGEM$704.18M-3.2-41.6%0.2%
PACB$640.04M-1.3-289.5%87.2%
SRDX$614.51M-34.8-15.6%19.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.2%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 3, 2026
|
EPS:-$0.29
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 29, 2025|
    Revenue: $61.25M+12.2%
    |
    EPS: $-0.50+47.1%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $61.08M+15.7%
    |
    EPS: $-0.30+15.4%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $52.41M+17.3%
    |
    EPS: $-0.46+35.3%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 5, 2025|
    Revenue: $204.73M+37.6%
    |
    EPS: $-1.64-78.3%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $54.57M+36.5%
    |
    EPS: $-0.34+70.0%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $52.80M+33.5%
    |
    EPS: $-0.26+100.0%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $44.69M+41.5%
    |
    EPS: $-0.34+13.3%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 8, 2024|
    Revenue: $148.73M+21.6%
    |
    EPS: $-0.92-1643.6%
    Miss